NCT05903092 - MOnaliZumab in Combination With durvAlumab (MEDI4736) Plus Platinum-based chemotheRapy for First-line Treatment of Extensive Stage Small Cell Lung Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 26, 2023

Primary Completion Date

January 3, 2026

Study Completion Date

January 3, 2027

Conditions

Small Cell Lung CancerSCLCExtensive Stage Small Cell Lung Cancer

Interventions

DRUG

Durvalumab

1500mg IV on Day 1 of every Cycle

DRUG

Monalizumab

1500mg IV on Day 1 of every Cycle

DRUG

Carboplatin or Cisplatin

"On Day 1 of Cycles 1-4 by IV:~Carboplatin: AUC 5-6 OR Cisplatin: 75-80mg/m\^2"

DRUG

Etoposide

80-100mg/m\^2 IV on Days 1-3 of Cycles 1-4

Trial Locations (4)

RECRUITING

University of Virginia Health System, Charlottesville

RECRUITING

Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis

RECRUITING

Karmanos Cancer Center (Wayne State University), Detroit

RECRUITING

University of Iowa Hospitals and Clinics, Iowa City